Since 1923, we have been focused on innovation and leadership in diabetes care. Today we have a broad portfolio of medicines.
Since the launch of our first pen needle in 1985, we have been committed to enhancing injection experience by putting technology in patient hands.
Access information on our products for rare bleeding disorders, growth hormone-related disorders, and women's health.
Find information on our treatment for chronic weight management in adults who are overweight with one weight-related comorbidity or obesity.
The link above used in conjunction with the FDA-approved product labeling may be used to determine U.S. patents associated with the corresponding U.S. marketed product.
Novo Nordisk Obesity Patient Ambassadors cover the largest obesity conference in the world.
There’s a lot of misinformation out there. Novo Nordisk’s Dr. Todd Hobbs shares the facts.
A photographer captures scenes of people living with diabetes around the world.
See the photos
An update on our efforts since making a pricing pledge in 2016
Affording your medicines
Access information on insurance and tools to help in getting the right care
Register for a copay card, access coupons and more
Our Position on Pricing and Affordability
Learn what we are doing to better support patients
West Lebanon, NH
live from ObesityWeek 2018 in Nashville 07 Jan 2019
Nordisk's operating profit decreased by 6% in Danish kroner and
increased by 2% in local currencies in the first nine months of
2018 01 Nov 2018
Read all Press Releases
Job Alert Be the first to know
All personal information reported in relation to a complaint or a
side effect will be processed in accordance with applicable data
protection legislation. For avoidance of doubt, “data protection
legislation” means the law governing the Novo Nordisk entity receiving
the complaint or report, not the residence or location of the
individual data subject submitting the report or complaint: